New drug combo shows promise for controlling mantle cell lymphoma
NCT ID NCT07199296
First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 34 times
Summary
This study is for people newly diagnosed with a type of blood cancer called mantle cell lymphoma that is not considered high-risk. It tests a combination of two drugs (orelabrutinib and rituximab) and may include a stem cell transplant using the patient's own cells. The goal is to see how well this approach shrinks or controls the cancer and how safe it is.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA (MCL) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital
RECRUITINGShanghai, 200025, China
Conditions
Explore the condition pages connected to this study.